| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |